Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiye Kangliugan is a traditional Uygur pharmaceutical preparation developed by the Xinjiang Uygur Autonomous Region Institute of Drug Research for the treatment of influenza and upper respiratory tract infections. The drug is primarily formulated as granules and is derived from the leaves of *Acer laevigatum* (Smooth Maple), a plant recognized in traditional Xinjiang medicine for its heat-clearing, detoxifying, and anti-inflammatory properties. Pharmacological studies indicate that the extract possesses broad-spectrum antiviral activity, particularly against influenza A and B viruses, by inhibiting viral replication and modulating the host's inflammatory response. It is clinically used to alleviate symptoms such as high fever, headache, cough, and sore throat associated with viral infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yiye Kangliugan.